Daejeon

Danurim Launches 'Black Ginseng Tea Total Infusion', a Red Ginseng Product with No Saponin Loss

Retrieved on: 
Thursday, November 2, 2023
Organic Food, Retail, Health, Manufacturing, Fitness & Nutrition, Other Manufacturing, Food, Beverage, Daejeon, Saponin, Prevalence, Water, Tea

Danurim , a Daejeon-based manufacturer of processed ginseng foods, is accelerating its global market entry with its Black Ginseng Tea Total Infusion.

Key Points: 
  • Danurim , a Daejeon-based manufacturer of processed ginseng foods, is accelerating its global market entry with its Black Ginseng Tea Total Infusion.
  • Black ginseng is made by fermenting 5-year-old fresh ginseng using Danurim's unique technology, which involves repeatedly steaming and drying the ginseng nine times in a process known as gujeunggupo.
  • Customers can enjoy black ginseng essence after steeping it for 6 hours by simply pouring boiling water over a root of black ginseng.
  • Because bioactive components are created during the steaming and drying process, black ginseng absorbs saponins at a faster rate than red ginseng.

Multimedia News Release: "Hello Shenyang" Global Promotional Campaign Held in Paris

Retrieved on: 
Thursday, November 2, 2023
Daejeon, Television, Government, China Europe International Business School, History, Information, Radio, Multimedia, Environment, Association Nationale pour le Développement des Arts de la Mode, Meinong Cultural and Creative Center, Societal transformation, Tourism, Investment, Creative industries, Shenhe District, Culture

SHENYANG, China, Nov. 1, 2023 /PRNewswire/ -- The event of the "Hello Shenyang" Global Promotional Campaign took place in Paris on the 26th.

Key Points: 
  • SHENYANG, China, Nov. 1, 2023 /PRNewswire/ -- The event of the "Hello Shenyang" Global Promotional Campaign took place in Paris on the 26th.
  • More than a hundred participants attended the event, including political and business representatives of France, and a trade and economy delegation from the city of Shenyang.
  • This year, the "Hello Shenyang" Global Promotional Campaign has already hosted events in places such as Tokyo of Japan and Daejeon-gwangyeoksi of South Korea.
  • Caption: "Hello Shenyang" global promotional campaign was held in Paris.

Microchip Teams Up with Intelligent Hardware Korea (IHWK) to Develop an Analog Compute Platform to Accelerate Edge AI/ML Inferencing

Retrieved on: 
Wednesday, September 13, 2023
Daejeon, SST, MCHP, DRAM, DSP, University, ML, APU, Microchip Technology, KAIST, Membrane, Yonsei University, VMM, Machine learning, Algorithm, NVM, Synapse, Artificial intelligence, AI, Memory, Video game, Computer data storage, Watt

Microchip Technology (Nasdaq: MCHP), via its Silicon Storage Technology (SST) subsidiary, is assisting with development of this platform by providing an evaluation system for its SuperFlash® memBrain™ neuromorphic memory solution .

Key Points: 
  • Microchip Technology (Nasdaq: MCHP), via its Silicon Storage Technology (SST) subsidiary, is assisting with development of this platform by providing an evaluation system for its SuperFlash® memBrain™ neuromorphic memory solution .
  • The solution is based on Microchip’s industry-proven nonvolatile memory (NVM) SuperFlash technology and is optimized to perform vector matrix multiplication (VMM) for neural networks through an analog in-memory compute approach.
  • The memBrain technology evaluation kit is designed to enable IHWK to demonstrate the absolute power efficiency of its neuromorphic computing platform for running inferencing algorithms at the edge.
  • IHWK is leveraging SuperFlash memory’s floating gate cells’ nonvolatility to achieve a new benchmark in low-power edge computing devices supporting machine learning inference using advanced ML models.

Advanced opening-up highlights Shenyang's role as global cooperation hub

Retrieved on: 
Friday, May 19, 2023
Workforce, Heart, Equipment, Maintenance, Daejeon, Sapporo, University of the Chinese Academy of Sciences, British Non-Ferrous Metals Research Association, FTZ, Kawasaki, BMW Brilliance, Central China, Shenhe District, Northeast Project of the Chinese Academy of Social Sciences, Lead, Shenyang Institute of Automation, Multimedia, UFT, Automation, Government, Belt and Road Initiative, Name, Republic, China Daily, BMW, Orangi Pilot Project, Regional Comprehensive Economic Partnership, CAS, United Kingdom, Science, Growth, Diagnosis, City, Belt, Transport, ZF Friedrichshafen, Fortune Global 500, State Council, Automotive industry, Oil, Cryptocurrency, Drug, Arms industry, 3D printing, Medical device, Film industry, Tiexi District

Its goal is to build itself into an international open and inclusive cosmopolitan city in Northeast Asia, according to the guidelines.

Key Points: 
  • Its goal is to build itself into an international open and inclusive cosmopolitan city in Northeast Asia, according to the guidelines.
  • To this end, the city is beefing up the Shenyang Area of China (Liaoning) Pilot Free Trade Zone.
  • Established in 2017, the FTZ Shenyang area makes full use of the combination of institutional innovation and the real economy's development.
  • Its production facility in Shenyang's Tiexi district, the 25th plant of BMW worldwide, is an exemplar of Sino-German cooperation in advanced manufacturing.

Daily Associated News: WANNABE GROUP Chairman Young-cheol Jeon, Social Contribution and Realization of Social Value Worldwide

Retrieved on: 
Friday, May 12, 2023
Volunteering, Daejeon, Capitalism, Fourth Industrial Revolution, Technological revolution, Multimedia, Organization, Tourism

SEOUL, South Korea, May 12, 2023 /PRNewswire/ -- WANNABE GROUP was established in 2016 as a concrete implementation of the "self-sustaining welfare system" that Chairman Young-cheol Jeon had been promoting to help youth in crisis. WANNABE GROUP aims to help people with weak information and technology skills to adapt to the times and settle down safely in the era of the Fourth Industrial Revolution.

Key Points: 
  • WANNABE GROUP aims to help people with weak information and technology skills to adapt to the times and settle down safely in the era of the Fourth Industrial Revolution.
  • All shares and profit distributions of the holding company, WANNABE DATA Co., Ltd. are reserved for the Kangaroo Foundation, a welfare foundation.
  • Chairman Young-cheol Jeon's management philosophy is that business is a social movement.
  • WANNABE GROUP has been conducting sharing campaigns for low-income people, youth in crisis, and the elderly across the country for a world that lives together.

Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022

Retrieved on: 
Saturday, December 10, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Therapy, Investigational New Drug, Drug discovery, Therapeutic index, IND, Poster, Pharmacology, GSPT1, Society, Daejeon, Sale, Health care reform, Cancer, American Society of Hematology, Research, TPD, FDA, COVID-19, Antibody, AML, TM, Safety, Acute myeloid leukemia, Drug resistance, ASH, Hematological Cancer Research Investment and Education Act, Risk, Vaccine, Pharmaceutical industry, Ørum

These data demonstrate we can increase the therapeutic index to improve the efficacy and tolerability of targeted protein degrader therapies with our TPD-squared approach, said Peter U.

Key Points: 
  • These data demonstrate we can increase the therapeutic index to improve the efficacy and tolerability of targeted protein degrader therapies with our TPD-squared approach, said Peter U.
  • Orum Therapeutics is a private, clinical-stage biotech pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD approach to provide antibody-enabled cell-specific delivery.
  • This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (Orum).
  • Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.

Orum Therapeutics Announces Presentation at ASH 2022 Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Health, Oncology, Health care reform, Research, Sale, Society, Drug resistance, Antibody, TPD, ASH, Acute myeloid leukemia, COVID-19, Therapy, Daejeon, Hematological Cancer Research Investment and Education Act, Pharmacology, Risk, American Society of Hematology, GSPT1, AML, Cancer, Pharmaceutical industry, Vaccine, Ørum

The data will be presented at the 64th American Society of Hematology (ASH 2022) Annual Meeting & Exposition taking place December 10-13, in New Orleans.

Key Points: 
  • The data will be presented at the 64th American Society of Hematology (ASH 2022) Annual Meeting & Exposition taking place December 10-13, in New Orleans.
  • Details of the presentation, which will be available in the poster hall and via the virtual meeting platform, are as follows:
    Session Name: 604.
  • Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
    The accepted abstract is available online through the ASH conference website: www.hematology.org/Annual-Meeting/Abstracts/ .
  • This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (Orum).

Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors

Retrieved on: 
Monday, October 31, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Control, CEO, TPD, Clinical trial, Cancer, Research, IND, Antibody, COVID-19, Risk, Health care reform, Safety, Sale, Therapy, GSPT1, Pharmacokinetics, Patient, AACR, Daejeon, Neoplasm, Hematological Cancer Research Investment and Education Act, Fine chemical, Vaccine, Pharmaceutical industry, Ørum

Orum Therapeutics , a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the first patient has been dosed with ORM-5029 in a Phase 1 clinical trial for patients with HER2-expressing advanced solid tumors.

Key Points: 
  • Orum Therapeutics , a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the first patient has been dosed with ORM-5029 in a Phase 1 clinical trial for patients with HER2-expressing advanced solid tumors.
  • The Phase 1 trial will help us to understand the potential clinical impact of ORM-5029 on HER2-expressing advanced tumors.
  • The first therapeutic candidates from the GSPT1 platform are in development for the treatment of solid tumors and hematologic cancers.
  • This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (Orum).

World Smart City Expo 2022 Closes Successfully Attracting Global Interest in K-Smart City

Retrieved on: 
Tuesday, September 20, 2022
Trucking, Technology, Transport, Mobile, Wireless, Construction & Property, Urban Planning, Hardware, Smart, City, Daejeon, Contract, KRW, Transport, UAM, Solution, Lists of countries and territories, Ministry (collective executive)

World Smart City Expo 2022 , held in KINTEX, South Korea, from August 31 to September 2, concluded with great success, marking the record high business deals sealed and number of visitors.

Key Points: 
  • World Smart City Expo 2022 , held in KINTEX, South Korea, from August 31 to September 2, concluded with great success, marking the record high business deals sealed and number of visitors.
  • This record high amount is 9.4% higher than KRW 107.7 billion (USD 77.4 million) achieved at World Smart City Expo 2019.
  • The Ministry of Land, Infrastructure and Transport of South Korea is promoting the 'Smart Challenge', which supports local governments to lead the spread of smart cities and smart city projects.
  • Smart solutions such as smart home developed by domestic and overseas smart city companies, UAM city air service, water-friendly information smart water purification plant, and urban water disaster response system were presented.

Orum Therapeutics to Participate at Investor Conferences in September

Retrieved on: 
Tuesday, September 6, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Daejeon, Hematological Cancer Research Investment and Education Act, TPD, Cancer, Antibody, GSPT1, Therapy, Vaccine

Orum Therapeutics , a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the Companys leadership will participate in the following investor conferences:

Key Points: 
  • Orum Therapeutics , a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the Companys leadership will participate in the following investor conferences:
    The presentation will take place at 4:20 pm ET on September 13th.
  • The company has developed new molecular glue degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway.
  • Orum Therapeutics is a private, clinical stage biotech pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD approach to provide dual-precision, antibody-enabled targeted protein degraders for cell-specific delivery.
  • The Companys proprietary platforms generated using the TPD approach include the GSPT1 platform, which generates first-in-class antibody drug conjugates.